Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-10-20 am EDT
|
5-day change | 1st Jan Change | ||
| 79.00 EUR | +0.08% |
|
+1.73% | +26.60% |
| Oct. 19 | This week's earnings calendar: CAC stocks, Meta, Tesla, SAP and Nestlé in the spotlight |  |
| Oct. 11 | Eurofins Scientific SE acquired xLabs, Inc. | CI |
| Market Cap | 13.71B 15.4B 12.71B 11.51B 21.65B 1,461B 21.97B 153B 59.86B 764B 57.75B 56.54B 2,437B | P/E 2026 * |
26.3x | P/E 2027 * | 20.8x |
|---|---|---|---|---|---|
| Enterprise Value | 17.16B 19.27B 15.91B 14.41B 27.09B 1,828B 27.48B 191B 74.9B 956B 72.26B 70.75B 3,049B | EV / Sales 2026 * |
2.28x | EV / Sales 2027 * | 2.12x |
| Free-Float |
60.34% | Yield 2026 * |
1.02% | Yield 2027 * | 1.15% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
OTC Markets
| ERFSF | Delayed | |
|
Xetra
| ESF0 | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | +0.08% | ||
| 1 week | +1.73% | ||
| Current month | +5.33% | ||
| 1 month | +3.35% | ||
| 3 months | +12.41% | ||
| 6 months | +13.12% | ||
| Current year | +26.60% |
| 1 week | 76.74 |  | 79.38 |
| 1 month | 73.3 | | 79.38 |
| Current year | 56.84 | | 79.38 |
| 1 year | 54.86 | | 79.38 |
| 3 years | 39.47 | | 79.38 |
| 5 years | 39.47 | | 118.12 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.08% | +1.73% | +26.36% | +66.39% | 15.37B | |
| +0.79% | -6.46% | +52.86% | +71.34% | 65.83B | |
| +1.92% | +8.89% | +12.90% | +82.75% | 51.87B | |
| +6.91% | +6.41% | +9.61% | +73.07% | 51.2B | |
| +0.74% | +2.15% | +30.95% | +43.43% | 43.76B | |
| +3.87% | +9.73% | +21.52% | +142.33% | 42.09B | |
| +7.91% | +1.34% | +263.31% | +577.76% | 39.04B | |
| -0.40% | +9.42% | +18.44% | +59.06% | 34B | |
| +3.84% | -4.94% | +42.35% | +8.92% | 25.2B | |
| +2.36% | +4.62% | +24.20% | +31.02% | 22.8B | |
| Average | +2.80% | +0.63% | +50.25% | +115.61% | 39.12B | |
| Weighted average by Cap. | +2.93% | +0.66% | +50.70% | +120.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.53B 8.46B 6.98B 6.33B 11.9B 803B 12.07B 83.82B 32.89B 420B 31.73B 31.07B 1,339B | 7.94B 8.92B 7.36B 6.67B 12.54B 846B 12.72B 88.37B 34.67B 442B 33.45B 32.75B 1,412B |
| Net income | 531M 596M 492M 446M 838M 56.55B 850M 5.91B 2.32B 29.57B 2.24B 2.19B 94.35B | 660M 741M 612M 554M 1.04B 70.26B 1.06B 7.34B 2.88B 36.74B 2.78B 2.72B 117B |
| Net Debt | 3.44B 3.87B 3.19B 2.89B 5.44B 367B 5.52B 38.32B 15.04B 192B 14.51B 14.2B 612B | 3.1B 3.48B 2.87B 2.6B 4.89B 330B 4.97B 34.48B 13.53B 173B 13.05B 12.78B 551B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-20 | €79.00 | +0.08% | 275,064 |
| 26-10-19 | €78.94 | +0.87% | 238,513 |
| 26-10-16 | €78.26 | -1.14% | 297,247 |
| 26-10-15 | €79.16 | +1.67% | 283,557 |
| 26-10-14 | €77.86 | -0.76% | 476,048 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
